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Summary
 
It is not known if immune response to T cell–defined human histocompatibility leukocyte an-
tigen (HLA) class I–restricted melanoma antigens leads to an expanded peripheral pool of T
cells in all patients, affects cytotoxic T lymphocyte (CTL) generation, and correlates with anti-
tumor response in metastatic lesions. To this end, a limiting dilution analysis technique was de-
veloped that allowed us to evaluate the same frequency of peptide-specific T cells as by staining
T cells with HLA–peptide tetrameric complexes. In four out of nine patients, Melan-A/Mart-
1
 
27–35
 
–specific CTL precursors (CTLp) were 
 
$
 
1/2,000 peripheral blood lymphocytes and
found mostly or only in the CD45RO
 
1 
 
memory T cell subset. In the remaining five patients, a
low (
 
,
 
1/40,000) peptide-specific CTLp frequency was measured, and the precursors were
only in the CD45RA
 
1 
 
naive T cell subset. Evaluation of CTL effector frequency after bulk
culture indicated that peptide-specific CTLs could be activated in all patients by using profes-
sional antigen-presenting cells as dendritic cells, but CTLp frequency determined the kinetics
of generation of specificity and the final number of effectors as evaluated by both limiting dilu-
tion analysis and staining with HLA-A
 
*
 
0201–Melan-A/Mart-1 tetrameric complexes. Immu-
nohistochemical analysis of 26 neoplastic lesions from the nine patients indicated absence of
tumor regression in most instances, even in patients with an expanded peripheral T cell pool to
Melan-A/Mart-1 and whose neoplastic lesions contained a high frequency of tetramer-positive
Melan-A/Mart-1–specific T cells. Furthermore, frequent lack of a “brisk” or “nonbrisk”
CD3
 
1
 
CD8
 
1
 
 T cell infiltrate or reduced/absent Melan-A/Mart-1 expression in several lesions
and lack of HLA class I antigens were found in some instances. Thus, expansion of peripheral
immune repertoire to Melan-A/Mart-1 takes place in some metastatic patients and leads to en-
hanced CTL induction after antigen-presenting cell–mediated selection, but, in most metastatic
lesions, it does not overcome tumor escape from immune surveillance.
Key words: melanoma • cytotoxic T lymphocytes • Melan-A/Mart-1 • peptide-speciﬁc CTL 
precursors • tumor escape
 
A
 
s shown initially by Clark et al. (1), the presence of
tumor-infiltrating lymphocytes (TILs)
 
1
 
 is an indepen-
dent prognostic factor in stage I vertical growth phase
(VGP) melanoma. The best probability of survival is associ-
ated with the “brisk” pattern (i.e., TILs are present
throughout the substance of the VGP or infiltrate the en-
tire base of the VGP tumor). A lower survival rate is ob-
served in “nonbrisk” cases (when TILs are present in one
or more foci of the VGP), and the lowest probability of
survival is found when TILs are coded as “absent” (1). An
 
1
 
Abbreviations used in this paper:
 
 DCs, dendritic cells; LDA, limiting dilution
analysis; p, precursor; TILs, tumor-infiltrating lymphocytes; VGP, vertical
growth phase. 
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association between TIL patterns and disease evolution has
been observed even when observing TILs in lymph node
metastases (in American Joint Committee on Cancer
[AJCC] stage III patients) (2). A possible interpretation of
these data is that brisk and, to a lesser extent, nonbrisk pat-
terns of TILs reflect a protective immune response to mel-
anoma antigens that results in control of tumor growth not
only in primary but even in metastatic lesions. This possi-
bility is in agreement with the large set of data indicating
clonal expansion of tumor-specific T cells in melanoma le-
sions (for review see reference 3). Furthermore, in at least
some melanoma patients, CTL clones and lines have been
derived even from peripheral blood after activation with
autologous tumor or tumor-derived peptides (4–6). In
these instances, differential kinetics of antigen-specific T
cell activation in vitro in patients versus healthy donors has
been described (7), suggesting tumor immunogenicity.
In spite of the data for involvement of the immune sys-
tem in controlling tumor growth, prognosis in metastatic
melanoma remains poor, with a median survival of 6 mo in
stage IV patients (8). Thus, in metastatic disease, tumor
progression occurs despite evidence consistent with tumor
immunogenicity, a paradox whose solution can now be
approached. In fact, the molecular characterization of
melanoma antigens and the identification of their CTL
epitopes (9, 10) allows us to evaluate whether the expan-
sion of the immune repertoire to a specific tumor antigen
occurs in melanoma patients and correlates with response at
the tumor site.
Among several antigens expressed by human melanoma,
Melan-A/Mart-1 (11) has attracted the interest of several
investigators due to its possible immunogenicity. This anti-
gen is frequently recognized by PBLs and TILs of mela-
noma patients (4, 7) that express the HLA restricting ele-
ment (HLA-A
 
*
 
0201) for its immunodominant peptide,
AAGIGILTV (6, 11).
In this study, we evaluated frequency in peripheral blood
of CTL precursors (CTLp) to Melan-A/Mart-1
 
27–35
 
 pep-
tide in metastatic melanoma patients and the possible rela-
tionship with immune response in metastatic lesions. To
this end, we dissected the relative contribution of memory
versus naive peptide–specific T cell subsets to the overall
PBL precursor frequency against Melan-A/Mart-1
 
27–35 
 
in
HLA-A
 
*
 
0201
 
1
 
 patients. The results indicated that in ap-
proximately half of patients, an expanded T cell population
to Melan-A/Mart-1 can be found in peripheral blood and
is characterized by peptide-specific T cells with a memory
phenotype. The CTLp frequency in blood explained both
kinetics of CTL induction in vitro and the number of
effectors that could be generated by selection with peptide-
loaded professional APCs. However, evidence of tumor re-
gression was missing in most tumor lesions, including those
isolated from the patients with an expanded T cell popula-
tion to Melan-A/Mart-1. These results contribute to an
explanation of tumor progression in human metastatic mel-
anoma in spite of evidence for peripheral immune response
to a tumor antigen.
 
Materials and Methods
 
Patients.
 
Nine metastatic melanoma patients, admitted to our
Institute (Istituto Nazionale per lo Studio e la Cura dei Tumori)
 
Table I.
 
Characteristics of Metastatic Melanoma Patients
 
Patient Sex/age
 
*
 
Primary
lesion
 
‡
 
Time from surgical
exeresis of primary
tumor to CTLp
evaluation
Current
status
 
§
 
Therapy at time of or
before isolation of
PBLs for CTLp
analysis
Progression of
disease
(site)
Time from CTLp
evaluation to exitus
 
mo mo
 
1 M/62 3.1/IV 2 DOD None
 
¶
 
Liver, s.c., bone 16
2 M/51 1.49/III 14 DOD None Brain 1
3 F/19 3.9/IV 6 DOD None Lung 4
4 F/57
 
.
 
4/V 18 DOD None s.c. 3.5
5 M/50 2/IV 26 AWD
 
i
 
TP5 LN, s.c.
6 F/63 NA 134 DOD None S.T., LN, peritoneum 5
7 M/64 2.94/IV 54 NED None —
8 F/39 3.97/IV 53 NED None —
9 F/65
 
.
 
4/V 6 DOD None s.c., lung 3
 
*
 
Age of the patients at the time PBLs for CTLp evaluation were isolated.
 
‡
 
Primary lesion thickness (mm)/Clark level (1). NA, not available.
 
§
 
DOD, dead of disease; NED, no evidence of disease; AWD, alive with disease.
 
i
 
This patient received TP5 (thymopentin, a peptide from thymic hormone) intravenously for 7 wk.
 
¶
 
Site of metastic lesions developing during progression of disease, in addition to lymph node (LN) metastases already diagnosed in all patients at time
of CTLp analysis. LN, lymph node; s.c., subcutaneous; S.T., soft tissue. 
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for surgery and chosen for expression of the HLA-A
 
*
 
0201
 
1
 
 allele
as determined by single-stranded oligonucleotide probe–PCR
typing (6), were selected for this study. Characteristics of the pa-
tients are described in Table I. At the time the PBLs were isolated
for CTLp frequency determination, all patients had already de-
veloped lymph node metastases (stage III, AJCC). Further pro-
gression of disease occurred in seven out of nine patients after
CTLp analysis (Table I). Six out of nine patients died of disease
between 1 and 16 mo after CTLp evaluation; the remaining three
patients are still alive at 41 mo (patient 5, alive with disease) and
38 mo (patients 7 and 8, both without evidence of disease) after
CTLp evaluation (Table I). None of the patients enrolled in this
study had been subjected to chemotherapy or any other therapy
with immunosuppressive activity before isolation of the PBLs
used for limiting dilution analysis (LDA; Table I).
 
Phenotype of Melanoma Cells and Lines.
 
Tumor lines used in
this study were isolated as previously described (6) from HLA-
A
 
*
 
0201
 
1
 
 patients admitted to our Institute for surgical treatment
of either primary or metastatic melanoma. Expression of Melan-
A/Mart-1 antigen in these lines, as well as in fresh tumor cells
isolated from some surgical specimens, was determined by intra-
cellular fluorescence analysis on saponin-permeabilized cells fol-
lowed by FACS™ analysis (Becton Dickinson) with the Melan-
A/Mart-1–specific mAb M27C10 (12), a gift of Dr. F. Marincola
(National Cancer Institute, Bethesda, MD). In addition, all lines
were found positive by flow cytometry for HLA-A2, CD54, and
lymphocyte function associate (LFA)-3, whereas none expressed
CD80. Fresh tumor cells from surgical specimens were also char-
acterized for HLA-A2 expression by flow cytometry after staining
with mAb CR11.351 (anti–HLA-A2) (13).
 
Peptides and APC Loading.
 
Melan-A/Mart-1
 
27–35
 
 (AAGIGILTV),
influenza A (Flu) matrix
 
58–66
 
 (GILGFVFTL), and tyrosinase
 
366–378
 
(YMNGTMSQV) peptides were used in this study (11, 14, 15).
All synthetic peptides were 
 
$
 
95% pure (PRIMM srl; San Raf-
faele Biomedical Science Park, Milan, Italy). Stock solutions of
peptides were set up in DMSO and kept at 
 
2
 
20
 
8
 
C. The concen-
trations of Melan-A/Mart-1
 
27–35
 
 (10 
 
m
 
g/ml) and Flu matrix
 
58–66
 
(5 
 
m
 
g/ml) peptides to load the TAP-deficient T2 cell line to be
used in LDA assays were determined by the binding assay based
on HLA-A2 stabilization and resulting in the same fluorescence
ratio of 3.2 as previously described (16). These peptide concen-
trations were also used to load other APCs used in the study.
 
Isolation of CD45RO
 
1
 
 and CD45RA
 
1
 
 T Cells by Negative Im-
munomagnetic Sorting.
 
5 
 
3
 
 10
 
6
 
 
 
T lymphocytes purified by nylon
wool column after Ficoll separation were resuspended in 100 
 
m
 
l
of PBS containing 0.5% autologous human serum and 0.6% acid
citrate dextrose (Baxter Healthcare Ltd.). To two identical ali-
quots of this cell suspension, 20 
 
m
 
L of MACS
 
®
 
 CD45RA or
MACS
 
®
 
 CD45RO Microbeads (Miltenyi Biotec) were added,
mixed, and allowed to incubate at 4
 
8
 
C for 15 min. After incuba-
tion, the cells were washed by adding 5 ml of PBS followed by
centrifugation at 800 rpm for 10 min at 4
 
8
 
C. The supernatant was
discarded and the cell pellet resuspended in 1 ml of cold PBS.
The separation column (MS type; Miltenyi Biotec) was primed
by washing with 1 ml of cold PBA and placed in a magnetic field.
The washed cell pellet, pretreated with either MACS
 
®
 
 CD45RA
or MACS
 
®
 
 CD45RO microbeads, was applied to the prefilled
columns. Cells expressing either CD45RA or CD45RO were
retained in the columns, whereas the negative fraction (i.e.,
CD45RO
 
1
 
 in columns loaded with CD45RA
 
1
 
-stained cells or
vice versa) was eluted and used for the LDA assays. Purity of the
two T cell subsets was assessed by flow cytometry and resulted in
 
$
 
98% in all instances.
 
Determination of Melan-A/Mart-1
 
27–35
 
–specific and Flu Matrix
 
58–66
 
–
specific CTLp Frequency in Peripheral Blood.
 
The HLA-A
 
*
 
0201
 
1 
 
TAP-
deficient T2 cell line, an effective APC for the activation of even
naive T cells and the generation of CTLs against peptides from
self- and non-self proteins (17), was used as APC for peptide pre-
sentation in all LDA assays. Lymphocytes isolated from peripheral
blood of melanoma patients or HLA-A
 
*
 
0201
 
1
 
 healthy donors by
Ficoll gradient centrifugation were used for determination of
peptide-specific CTLp frequency after monocyte depletion. The
LDA technique for determination of peptide-specific CTLp
frequency was performed as described (6, 16). After 4 wk of cul-
ture, each of the replicate wells of all LDA cultures was split into
two aliquots and tested against an empty or peptide-loaded
HLA-A
 
*
 
0201
 
1
 
 LCL (9742 LCL). Melan-A/Mart-1
 
27–35
 
 or Flu
matrix
 
58–66
 
 peptides were used depending on the LDA sets. To
evaluate the frequency of HLA-A2–restricted precursors, in some
experiments the split well analysis was performed by testing lysis
of an HLA-A
 
*
 
0201
 
1
 
Melan-A/Mart-1
 
1
 
 melanoma that was
or was not preincubated with an anti–HLA-A2 A28 mAb
(CR11.351). The cytolytic assay was performed as described (6,
16). To increase the efficiency of the assay, all cytolytic tests, in-
volving either 9742 LCL or melanoma cells as targets, were per-
formed in the presence of 3 
 
3
 
 10
 
2
 
 targets per well. The threshold
of significant lysis, criteria to score a well as containing a peptide-
specific CTLp, and data analysis for CTLp frequency determina-
tion have been described elsewhere (6, 16). As developed, this
LDA assay cannot detect CTLp frequencies 
 
,
 
1/200,000. This
LDA technique was also used to evaluate frequency of CTL ef-
fectors in bulk T cell cultures. In these instances, T cells from
bulk cultures were seeded in LDA sets and tested for specificity
by the split well technique after 1 wk.
 
T Cell Cultures.
 
After monocyte depletion, PBLs were cul-
tured in 24-well plates (Costar Corp.) at 10
 
6 
 
cells/ml in 2 ml of
RPMI 1640 supplemented with 10% heat-inactivated human se-
rum in the presence of 0.5 
 
3 
 
10
 
6
 
/ml irradiated, peptide-loaded
T2 cells. Independent cultures were set up using T2, either empty or
loaded with Melan-A/Mart-1
 
27–35
 
 or tyrosinase
 
366–378
 
 peptides.
Low dose (10 U/ml) IL-2 was added on day 2 to all cultures. All
cultures were then restimulated weekly with peptide-loaded or
empty T2 cells. The resulting T cell lines were tested weekly
from days 21–70 for specificity (by 
 
51
 
Cr-release assays) on pep-
tide-loaded or empty 9742 LCL cells. Specificity of these T cell
lines was also tested on HLA-A
 
*
 
0201
 
1
 
 melanomas that did or did
not express Melan-A/Mart-1. HLA-A2 restriction of melanoma
lysis was checked by comparing lysis of melanomas that were or
were not preincubated with mAb CR11.351. Induction of Melan-
A/Mart-1
 
27–35
 
–specific CTLs was also carried out in two patients
(patients 7 and 8) by coculture with peptide-loaded autologous
dendritic cells (DCs) derived from CD34
 
1
 
 progenitors or mono-
cytes. DCs were differentiated from purified CD34
 
1
 
 progenitors
or monocytes as recently described (16). CD34
 
1
 
 progenitors
were initially mobilized by G-CSF treatment (a written informed
consent was signed by patients for this treatment). Phenotype of
DCs and monocytes was evaluated by flow cytometry with mAbs
to CD1a (Coulter Immunology), CD14, HLA-DR, HLA-DQ
(Becton Dickinson), CD40, CD80 (Serotec Ltd.), CD86 (Ancell),
and CD54 (Immunotech). Control cultures from the same two
patients were also set up with autologous fresh monocytes loaded
with either Melan-A/Mart-1
 
27–35
 
 or Flu matrix
 
58–66
 
 peptides. All
cultures, set up with autologous DCs or monocytes as APCs,
were restimulated weekly with fresh, peptide-loaded monocytes.
 
Flow Cytometry Analysis after T Cell Staining with HLA–Peptide
Tetrameric Complexes.
 
HLA–peptide tetrameric complexes were 
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synthesized as described (18). Staining of PBLs, TILs, and T cell
lines was performed by incubating for 30 min in ice with PE-
conjugated HLA-A
 
*
 
0201–Melan-A/Mart-1
 
26-35
 
 tetramers. The
modified Melan-A/Mart-1
 
26-35
 
 peptide (ELAGIGILTV) used for
refolding the HLA–peptide complex has been shown to increase
the binding affinity for HLA-A
 
*
 
0201 without affecting CTL rec-
ognition (19). Negative controls for tetramer staining included
PBLs from HLA-A
 
*
 
0201–negative healthy donors and HLA-
A2–restricted CTL clones directed to tyrosinase peptides (6); a
Melan-A/Mart-1
 
27–35
 
–specific CTL clone, A83 (16), was used as
positive control. Two-color fluorescence analysis was performed
in some instances by staining T cell lines with FITC-conjugated
anti-CD8 and PE-conjugated tetramers. At least 10
 
5 cells were
analyzed for staining with PE-conjugated tetramers.
Immunohistochemical Analysis of Primary and Metastatic Melanoma
Lesions. Immunohistochemical analysis was performed on rou-
tinely formalin- or Bouin’s-fixed and paraffin-embedded speci-
mens. 4-mm-thick tissue sections were deparaffinized through
graded series of ethanol passages and rehydrated in distilled water.
Endogenous peroxidase was inhibited by a 30-min incubation in
methanol containing 0.3% H2O2. To optimize immunodetection
of Melan-A/Mart-1, gp100, and CD8, nonenzymatic antigen
unmasking was performed by heating tissue sections at 958C for 6
min in an autoclave in 5 mM citrate buffer, pH 6 (20). After
cooling, sections were incubated with normal goat serum (1:50;
DAKO Corp.) diluted in PBS containing 1% BSA for 30 min.
Primary antibody incubation was performed overnight at 48C
with the following antibodies: M27C10 (12), anti–Melan-A/
Mart-1 (1:50), HMB45, anti-gp100 (1:25; DAKO Corp.), and
CD8 (1:20; DAKO Corp.). Staining with polyclonal antibody
CD3 (DAKO Corp.) was performed after 0.1% trypsin treatment
for 5 min as described for antigen unmasking. Sections were sub-
sequently rinsed three times in PBS plus Triton X-100 and
treated with biotinylated goat anti–mouse Ig (1:100; DAKO
Corp.) or with biotinylated goat anti–rabbit Ig (1:200; DAKO
Corp.) for CD3 staining. The slides were then covered with
streptavidin–horseradish peroxidase (1:300; DAKO Corp.) for 30
min and finally visualized with the use of red 3-amino-9-ethyl-
carbazole (Sigma Chemical Co.) in 0.05 M acetate buffer con-
taining 0.015% H2O2. Sections were then counterstained with
hematoxylin and mounted with glycerine-gelatin 4. Tissue sec-
tions subjected to the same treatment but without incubation
with primary antibody were used as negative controls. Positive
controls were a reactive lymph node for CD3 and CD8 and a
Melan-A/Mart-11 human melanoma cell line grown in nude
mice that was subsequently formalin fixed and paraffin embedded
for Melan-A/Mart-1.
Results
An Expanded Pool of Melan-A/Mart-127–35–specific Memory
T Cells Can Be Found in Peripheral Blood of a Fraction of
HLA-A*02011 Metastatic Melanoma Patients. Using LDA,
we evaluated the CTLp frequency against a peptide (AA-
GIGILTV in the context of HLA-A*0201) from the mel-
anocyte lineage–specific antigen Melan-A/Mart-1 in pe-
ripheral blood of nine HLA-A*02011 metastatic melanoma
patients. Two CTLp frequency groups were found (Table
II): a group (patients 1, 2, 6, and 9) with high frequency of
CTLp to Melan-A/Mart-127–35 (between 1/1,400 and
1/2,225) and a group (patients 3, 4, 5, 7, and 8) with low
frequency of CTLp (between 1/40,000 and ,1/200,000)
to the same antigen. In agreement with our previous results
(6, 21), independent LDA assays performed using PBLs iso-
lated from the same patient a few months apart indicated
that the CTLp frequency remained in the same range in
each of the two groups of patients (data not shown). Fur-
thermore, staining with Melan-A/Mart-1–HLA-A*0201
tetrameric complexes indicated a frequency of peptide-spe-
cific T cells of 1/1,456 and 1/1,843 in PBLs of patients 6
and 9, respectively, in good agreement with CTLp fre-
quency by LDA. By using lymphocytes from the same
blood sample, CTLp analysis was reassessed in sorted mem-
ory (CD45RO1) and naive (CD45RA1) T cell subsets. In
two patients from the high CTLp frequency group, Melan-
A/Mart-127–35–specific CTLp were mostly (patient 2) or
only (patient 6) found in the CD45RO1 memory T cell
subset (Table II). By contrast, in two patients from the low
CTLp frequency group (patients 7 and 8), Melan-A/Mart-
127–35–specific CTLp were detected only in the CD45RA1
naive T cell subset.
Low frequency of CTLp to Melan-A/Mart-127–35, de-
tected in patients 3, 4, 5, 7, and 8, was not the result
of nonspecific immune suppression preventing precursor
growth or development of cytolytic function in LDA cul-
tures. In fact, in these patients, the CTLp frequency of a
different HLA-A*0201–restricted T cell epitope (the im-
munodominant Flu matrix58–66 peptide) was in the same
range, or even higher, than that found in a panel of HLA-
A*02011 healthy donors (Table III). Taken together, these
data indicate that expansion of the Melan-A/Mart-127–35–
specific T cell population occurs in a fraction of metastatic
Table II. Frequency of Peptide-specific CTLp Directed to Melan-
A/Mart-127–35 Peptide in Peripheral Blood of Melanoma Patients
Patient
Frequency of CTLp to
Melan-A/Mart-127–35 peptide in
PBLs
CD45RO1
T cell subset
CD45RA1
T cell subset
1 1/1,404 ND ND
2 1/1,708 1/1,118 1/56,787
6 1/1,399 1/879 ,1/200,000
9 1/2,225 ND ND
3 1/43,717 ND ND
4 1/42,600 ND ND
5 1/117,555 ND ND
7 ,1/200,000 ,1/200,000 1/42,919
8 1/96,691 ,1/200,000 1/22,430
CTLp frequency was evaluated in peripheral blood by LDA as de-
scribed in Materials and Methods by using peptide-loaded T2 cells as
APCs. Results are expressed as peptide-specific CTL precursors/PBLs.
In patients 6 and 9, frequency of Melan-A/Mart-1–specific T cells in
PBLs was 1/1,456 and 1/1,843, respectively, by staining with HLA-
A*0201–Melan-A/Mart-126–35 tetrameric complexes.655 Anichini et al.
melanoma patients, as indicated by a high-frequency pe-
ripheral pool of antigen-specific T cells with a memory
phenotype.
A Low Frequency of CTLp to Melan-A/Mart-127–35 Reflects
a Naive Immune Repertoire Requiring Professional APCs for
CTL Activation. In patients of the low CTLp frequency
group, Melan-A/Mart-1–specific CTLs were activated in
bulk culture with professional APCs (DCs and T2) versus
nonprofessional APCs (monocytes), and then the frequency
of CTL effectors was quantitated by LDA. As shown in
Table IV, after 42 d of bulk culture, Melan-A/Mart-127–35–
specific effectors were expanded in patient 7 to a final fre-
quency ranging from 1/63 to 1/142 after activation with
peptide-loaded T2 or autologous DCs. No peptide-specific
CTLs were found by LDA in cultures activated with pep-
tide-loaded monocytes. Similar results were obtained with
another patient in the low-frequency group (data not
shown). In contrast, nonprofessional APCs (monocytes)
could reactivate and expand Flu matrix58–66–specific T cells
(a memory response that depends on previous viral expo-
sure and does not require professional APCs for reactiva-
tion). In fact, a Flu matrix–specific CTL effector frequency
of 1/1,190 was found in patient 7 after 21 d of bulk culture
(Table IV), in comparison to a precursor frequency of
1/5,471 in fresh PBLs (Table III). These data indicate that
patients with low CTLp frequency of Melan-A/Mart-127–35
are endowed with only a naive immune repertoire, made
up of rare precursors that require professional APCs for
priming and proliferation.
Impact of CTLp Frequency on Kinetics of Melan-A/Mart-
1–specific CTL Generation in Bulk Culture. Kinetics of ac-
tivation of Melan-A/Mart-127–35–specific CTLs in bulk
culture was compared in patients with low and high CTLp
frequency. T2 cells (shown in Table IV to have the same
APC efficiency as DCs) were used as stimulators after load-
ing with Melan-A/Mart-127–35 or control tyrosinase366–378
peptide. In T cell cultures from patients 1 and 2 (two patients
with high CTLp frequency), Melan-A/Mart-127–35 specific-
ity was already evident on day 21 (data not shown) and was
confirmed on days 28 and 36 of culture (Table V). Peptide
specificity was documented by recognition of peptide-loaded
9742 LCL, HLA-A2–restricted lysis of HLA-A*02011Melan-
A/Mart-11 tumors (INT-MEL-8 and INT-MEL-9), and
absence of HLA-restricted lysis on an HLA-A*02011Melan-
A/Mart-12 melanoma (INT-MEL-10) (Table V). By con-
trast, T cell cultures from patients 3, 4, and 5 (all with low
CTLp frequency) lacked peptide specificity against 9742
LCL targets, either on day 28 or 36. T cell cultures from
patient 3 showed HLA-A2–restricted lysis of two Melan-
Table III. Frequency of Peptide-specific CTLp Directed to Flu 
Matrix58–66 in the Context of HLA-A*0201 in Melanoma Patients 
and Healthy Donors
Subject Frequency of CTLp to Flu matrix58–66 peptide
Patient 3 1/4,195
Patient 4 1/7,426
Patient 5 1/6,967
Patient 7 1/5,471
Patient 8 1/4,435
Healthy donor 1 1/10,506
Healthy donor 2 1/5,591
Healthy donor 3 1/13,177
Healthy donor 4 1/15,246
Healthy donor 5 1/7,588
Healthy donor 6 1/13,440
CTLp frequency was evaluated in peripheral blood by LDA as de-
scribed in Materials and Methods using peptide-loaded T2 cells as
APCs. Results are expressed as peptide-specific CTLp/PBLs.
Table IV. Frequency of Melan-A/Mart-127–35–specific CTL Effectors on Day 42 of Bulk Culture after T Cell Activation with
Different APCs
APCs
Peptide used to load APCs
in bulk culture
Frequency, after bulk culture, of
peptide-specific CTL effectors directed to
Melan-A/Mart-127–35 peptide Influenza matrix58–66 peptide
T2 cells Melan-A/Mart-127–35 1/69 ND
CD341-derived autologous DCs Melan-A/Mart-127–35 1/63 ND
Monocyte-derived autologous DCs Melan-A/Mart-127–35 1/142 ND
Fresh autologous monocytes Melan-A/Mart-127–35 ,1/200,000 ND
Fresh autologous monocytes Flu matrix58–66 1/1,190
Frequency of Melan-A/Mart-127–35- and Flu matrix58–66–specific effectors was determined respectively on days 42 and 21 of bulk T cell culture. Re-
sponder lymphocytes were from one of the patients (patient 7) in the low CTLp frequency subset. Phenotype of all APCs was checked by flow cy-
tometry. CD341 and monocyte-derived DCs expressed CD1a, CD40, CD80, CD86, CD54, HLA-DR, and HLA-DQ antigens. T2 cells expressed
CD40, CD80, CD86, and CD54. CD14 was expressed only by monocytes, which were also positive for HLA-DR and CD54 but lacked CD40,
CD80, CD86, and HLA-DQ antigens.656 Expanded T Cell Population to Melan-A/Mart-1
Table V. Specificity of T Cell Lines Activated with Peptide-loaded T2 Cells
PBLs
from
patient *T2 cells loaded with
‡Test
day
§Targets
9742 LCL iINT-MEL-8 iINT-MEL-9 iINT-MEL-10
—
1Melan-A/
Mart-127–35
1Tyrosin-
ase366–378 2mAb 1mAb 2mAb 1mAb 2mAb 1mAb
1 — 28 2¶ 0 3 2 1 19 17 2 1
Melan-A/Mart-127–35 28 6 39 4 70 6 47 15 81 1
Tyrosinase366–378 28 2 0 3 4 4 12 8 5 4
1 — 36 7 12 7 3 7 22 26 1 0
Melan-A/Mart-127–35 36 4 80 6 55 6 51 3 10
Tyrosinase366–378 36 9 9 12 2 5 5 3 1 0
2 — 28 2 1 3 10 7 10 11 7 5
Melan-A/Mart-127–35 28 6 17 8 69 33 57 19 13 10
Tyrosinase366–378 2 8 2 2 6 4 5 3 4 3 01 51 31 6
2 — 36 9 12 10 9 11 48 41 6 5
Melan-A/Mart-127–35 36 29 95 24 81 47 86 23 13 17
Tyrosinase366–378 36 12 17 78 55 17 82 17 88
3 — 28 3 2 3 18 9 14 16 7 11
Melan-A/Mart-127–35 28 14 16 15 28 12 36 25 15 16
Tyrosinase366–378 2 8 0 0 1 1 0 2 9321
3 — 36 5 1 2 9 12 48 49 8 16
Melan-A/Mart-127–35 36 10 6 8 36 21 88 68 15 14
Tyrosinase366–378 36 3 0 0 6 11 28 30 2 2
3 Melan-A/Mart-127–35 49 2 55 5 80 15 79 50 ND ND
4 — 2 8 0 0 0 2 1 0200
Melan-A/Mart-127–35 2 8 0 0 0 3 4 3 6 1 72 92 63 1
Tyrosinase366–378 2 8 4 2 7 2 8 1 9 2 82 32 51 7
4 — 3 6 3 3 2 2 4 8900
Melan-A/Mart-127–35 3 6 4 7 3 4 2 4 4 5 26 03 83 8
Tyrosinase366–378 3 6 3 1 2 2 4 2 1 3 83 11 21 3
5 — 28 1 0 2 4 3 37 46 5 7
Melan-A/Mart-127–35 28 2 0 2 11 3 28 35 2 6
Tyrosinase366–378 28 16 13 22 75 73 31 44 12 15
5 — 36 3 2 1 7 8 52 67 0 1
Melan-A/Mart-127–35 36 1 1 0 2 4 47 56 0 0
Tyrosinase366–378 36 61 46 49 66 71 60 60 18 26
*T cell cultures were set up by coculture of patients’ PBLs with T2 cells either unloaded or loaded with peptides Melan-A/Mart-127–35 or
tyrosinase366–378.
‡T cell lines were tested for specificity after the indicated time of culture.
§Targets were HLA-A*02011 9742 LCL (either unloaded or loaded with Melan-A/Mart-127–35 or tyrosinase366–378 peptides), two HLA-A*02011
Melan-A/Mart-11 melanomas (INT-MEL-8 and INT-MEL-9), and one HLA-A*02011Melan-A/Mart-12 melanoma (INT-MEL-10).
iLysis of melanoma cells was tested after target preincubation (1mAb) or no preincubation (2mAb) with anti–HLA-A2 A28 mAb CR11.351.
¶Results expressed as percent lysis in a 4-h 51Cr-release assay. E/T ratio was 10:1. Values in bold represent significant lysis of peptide-loaded 9742
LCL in comparison to empty targets or lysis of melanoma cells significantly inhibited by mAb CR11.351 (student-Newman-Kevls [SNK] test, P 5 0.01).
A/Mart-11 melanomas on days 28 and 36, but evidence of
peptide specificity on peptide-loaded 9742 LCL was ob-
tained only on day 49 of culture (Table V). In other pa-
tients of the low CTLp frequency group, peptide specific-
ity on 9742 LCL and HLA-A2–restricted recognition of
tumors required up to 70 d of bulk culture to be obtained
(data not shown). These data indicate that a high frequency
of peptide-specific CTLp in blood of patients correlates
with faster kinetics of generation of antigen specificity after
in-vitro T cell activation with peptide-loaded APCs.657 Anichini et al.
Impact of CTLp Frequency on CTL Effector Frequency.
CTL effector frequencies in bulk T cell cultures were com-
pared in patients with low or high precursor frequency by
LDA and T cell staining with Melan-A/Mart-1–HLA-
A*0201 tetrameric complexes (Table VI). In day 28 bulk
cultures of three patients of the high CTLp group, peptide-
specific CTL effectors were between 1/10 and 1/24. By
contrast, in day 28 bulk cultures from patients of the low
CTLp group, the peptide-specific effectors were between
1/576 and 1/4,531. In two patients (patients 2 and 6), eval-
uation of CTL effector frequency by LDA was performed
by two distinct readout systems: differential lysis of peptide-
loaded or nonloaded 9742 LCL and differential recognition
of HLA-A*02011Melan-A/Mart-11 melanoma cells that
were or were not preincubated with an anti–HLA-A2
mAb. Effector frequencies were similar by both readout
systems (Table VI). Control LDA assays, performed on T
cell cultures activated by empty T2 (Table VI), gave no de-
tectable peptide-specific effector frequency (patients 1, 4, 5,
7, and 8). Furthermore, frequency evaluation by LDA
and Melan-A/Mart-1–HLA-A*0201 tetrameric complexes
gave similar results (Table VI). This indicated that essen-
tially all T cells expressing a Melan-A/Mart-1–specific
TCR, as identified by tetrameric complexes, could also be
functionally identified by our LDA approach. In addition,
T cell staining with tetrameric complexes allowed us to fol-
low the evolution in culture of Melan-A/Mart-1–specific
T cells during selection with peptide-loaded APCs. As
shown in Fig. 1, the number of peptide-specific T cells rose
from 1/599 (Fig. 1 E, day 14) to 1/11 (Fig. 1 G, day 56) in
a T cell culture from patient 6 and from 1/76 (Fig. 1 H,
day 14) to 1/1.36 (Fig. 1 J, day 42) in the T cell culture of
patient 2. This indicates that in the patients with high pre-
cursor frequency, T cell activation with peptide-loaded T2
cells leads to early and progressive expansion of peptide-
specific T cells. Taken together, these data suggest that a
high CTL effector frequency, after APC-mediated T cell
selection, can be achieved only in patients with a high
CTLp frequency in blood. Thus, presence of an expanded
peripheral pool of T cells to a tumor antigen is an impor-
tant requisite for efficient in vitro selection of antitumor T
cells from peripheral blood of patients.
Melan-A/Mart-127–35–specific CTLs Can Be Isolated from
Metastatic Lesions of Patients with High Frequency of CTLp to
the Same Antigen. T cells isolated from metastases of pa-
tients 1 and 2 (two patients of the high CTLp frequency
group) and patient 3 (with low CTLp frequency) were
tested for specificity after 3 wk of selection in bulk culture
with Melan-A/Mart-127–35–loaded T2 cells as APCs. The
T cell lines from lesions of patients 1 and 2 specifically rec-
ognized 9742 LCL loaded with Melan-A/Mart-127–35 pep-
tide and lysed the two Melan-A/Mart-11 tumors INT-
MEL-8 and INT-MEL-9 in an HLA-A2–restricted fashion
(Table VII). By contrast, only nonspecific lysis on all targets
by T cells isolated from a lymph node metastasis of patient
3 was observed. These findings were confirmed even after
36 d of culture (data not shown). Staining of TILs from
the subcutaneous lesion of patient 1 with Melan-A/Mart-
1–HLA-A*0201 tetrameric complexes revealed a frequency
of 1/17.6 peptide-specific T cells (Fig. 1 D), thus indicat-
Table VI. Frequency of Melan-A/Mart-127–35–specific CTL Effectors in Day 28 Bulk Cultures after T Cell Activation with Peptide-loaded 
T2 Cells: Comparison of LDA and T Cell Staining with Melan-A/Mart-1–HLA-A*0201 Tetrameric Complexes
Patient
*Evaluation by LDA iEvaluation by HLA-A*0201–
Melan-A/Mart-126–35
tetrameric complexes ‡Peptide-specific CTL effector
frequency after lymphocyte
activation with §HLA-A2–restricted CTL effector
frequency after lymphocyte activation
with peptide-loaded T2 cells
Peptide-specific effector frequency
after lymphocyte activation with
peptide-loaded T2 cells Peptide-loaded T2 Empty T2
1 1/9.8 ,1/200,000 ND 1/10.3
2 1/15.8 ND 1/14.2 1/10.4
6 1/24 ND 1/42 1/23.1
3 1/4,531 ND ND ND
4 1/576 ,1/200,000 ND ND
5 1/1,093 ,1/200,000 ND 1/961
7 1/1,509 ,1/200,000 ND ND
8 1/831 ,1/200,000 ND 1/685
Patients’ PBLs were cultured for 28 d in bulk culture in the presence of T2 cells either empty or loaded with Melan-A/Mart-127–35 peptide.
Frequency of peptide-specific CTL effectors in bulk cultures was evaluated by LDA or by HLA-A*0201–Melan-A/Mart-1 tetramer staining.
*Split well analysis was performed by ‡comparing lysis of empty and Melan-A/Mart-127–35–loaded 9742 LCL or §comparing lysis of the HLA-
A*02011Melan-A/Mart-11 melanoma INT-MEL-8 that was or was not preincubated with anti–HLA-A2 A28 mAb CR11.351.
iFrequency of peptide-specific T cells was evaluated by staining with PE-conjugated HLA-A*0201–Melan-A/Mart-126–35 tetrameric complexes. All
T cell lines were .99% CD31 at time of analysis.658 Expanded T Cell Population to Melan-A/Mart-1
ing a very high enrichment in comparison to frequency of
CTLp to the same antigen detected in peripheral blood of
the same patient (1/1,404; Table II). Thus, patients with an
expanded peripheral pool of Melan-A/Mart-127–35–specific
T cells do have peptide-specific T cells in their metastatic
lesions. Furthermore, the CTLp present in metastatic le-
sions could be readily activated by appropriate antigen pre-
sentation to acquire effector function with a fast kinetics of
proliferation, suggesting absence of any irreversible func-
tional block.
Immunohistochemical Analysis of Metastatic Lesions. To eval-
uate  the relationship between the expanded peripheral pool
of T cells to Melan-A/Mart-1 and in vivo response to tu-
mor lesions, all available primary and metastatic lesions iso-
lated during tumor progression from the nine patients were
analyzed by immunohistochemistry. To this end, the brisk/
nonbrisk/absent code for defining patterns of infiltrating T
cells was adopted (1, 2). A common pattern emerged: in all
patients, including those with high frequency of CTLp to
Melan-A/Mart-1, evidence of tumor regression/necrosis
was often completely lacking or, with few exceptions, ap-
peared to involve only a minor portion of the area contain-
ing neoplastic cells in each lesion (Table VIII). Moreover,
tumor regression, when present, often appeared as areas of
coagulative necrosis, sometimes admixed with hemorrhage,
that were never infiltrated or immediately surrounded by
CD31 lymphocytes, even in the lesions containing brisk or
nonbrisk CD31CD81 T cells. Furthermore, with the ex-
ception of all lesions from patient 9, which lacked HLA
class I antigens, including HLA-A2, all other lesions that
Figure 1. Identification of Melan-A/Mart-1–specific T cells in T cell lines from melanoma patients by Melan-A/Mart-126–35–HLA-A*0201 tetrameric
complexes. Lymphocytes from peripheral blood of an HLA-A*02012 healthy donor (A) did not stain with the tetramer–PE, whereas 100% of cells from
a Melan-A/Mart-127–35–specific CTL clone A83 (B) were tetramer positive. In a T cell line selected in vitro for Melan-A/Mart-127–35 specificity (from
patient 2, week 5 of culture), all tetramer-positive cells were within the CD81 subset (C). Fresh TILs from a subcutaneous metastatic lesion (lesion 3) of
patient 1 contained 5.68% of tetramer-positive T cells (D). T cell lines from two melanoma patients were selected in vitro with Melan-A/Mart-127–35–
loaded T2 line as APCs and analyzed for tetramer staining at different times during culture (E–J). A T cell line from patient 6 was analyzed on weeks 2
(E), 4 (F), and 8 (G) of culture, and a T cell line from patient 2 was analyzed on weeks 2 (H), 4 (I), and 6 (J) of culture. The proportion of Mart-126–35–
HLA-A*0201 tetramer–PE-positive T cells in each line is shown together with conversion to frequency. At least 105 cells were analyzed in each panel.
The proportion of CD31 T cells was 97% in fresh TILs from patient 1 (D) and .99% in all T cell lines from the two patients (C, E–J), with the excep-
tion of the line shown in H (CD31 5 78.4%).659 Anichini et al.
could be analyzed expressed HLA-A2, suggesting that in
these instances T cell epitope presentation was not im-
paired in tumor cells (Table VIII).
In patient 1, the primary lesion (lesion 1) and a satellitosis
(lesion 2) were removed 2 mo before CTLp evaluation
(Table VIII). The first lesion had an absent pattern of
CD31 T cells and Melan-A/Mart-1 antigen expressed on
20% of the neoplastic cells. The satellitosis was nonbrisk for
CD31 T cells, but CD81 T cells represented only 30% of
them and Melan-A/Mart-1 was not expressed. A subcuta-
neous lesion (lesion 3) isolated 1 wk before CTLp evalua-
tion was Melan-A/Mart-11 and expressed HLA-A2 on the
tumor and 30% of CD81 cells among the nonbrisk CD31
infiltrate. However, no evidence of tumor destruction was
observed, even though this same lesion contained a high
frequency of Melan-A/Mart-1–specific CTLp (Table VII,
Fig. 1). A lymph node metastasis (lesion 4) was almost
completely negative for Melan-A/Mart-1 and absent for
CD31 T cells. In the same patient, in spite of an expanded
T cell population to Melan-A/Mart-1 in peripheral blood,
three additional subcutaneous metastases developed within
6 mo of CTLp analysis. Two of these lesions expressed
Melan-A/Mart-1, but no evidence of tumor regression or
destruction was found, although all lesions contained a
brisk CD31CD81 infiltrate (Table VIII, lesions 5–7; Fig. 2,
A–D).
In patient 2, a lymph node metastasis removed 6 d after
CTLp analysis (Table VIII, lesion 9) showed tumor regres-
sion affecting 50% of the neoplastic tissue. Although this le-
sion contained Melan-A/Mart-1–specific CTLp (Table
VII), the necrotic area appeared to be the result of an isch-
emic lesion and not of an immune response (Fig. 2 H). In
fact, the nonbrisk CD31CD81 infiltrate (Fig. 2, E and F)
did not surround nor infiltrate the necrotic area, which was
instead surrounded by scattered granulocytes (Fig. 2 H).
The tumor cells were HLA-A21, and some areas showed a
weak staining for Melan-A/Mart-1 (Table VIII and Fig. 2
G), suggesting a possible tumor escape mechanism. In pa-
tient 6, an absent pattern of CD31 T cells was found in an
HLA-A21 soft tissue metastasis lacking Melan-A/Mart-1
and removed 4 d after CTLp analysis (Table VIII, lesion
11), as well as almost no tumor regression but a 10% sclero-
sis. Again, the lack of Melan-A/Mart-1 suggests a possible
tumor escape mechanism. In patient 9, three synchronous
lesions were removed, including the primary tumor (lesion
12) and two metastases (lesions 13 and 14). All of these le-
sions were Melan-A/Mart-11 and lacked HLA class I, in-
cluding HLA-A2, suggesting another mechanism of tumor
Table VII. Melan-A/Mart-127–35–specific CTLs Can Be Isolated from Metastatic Lesions of Patients with High Frequency of CTLp to the
Same Antigen
Patient
*T cells
isolated
from
‡Lesion
number
Classification
of infiltrating
T cells
§T cells
cocultured with
iLysis of
9742 LCL
loaded
with INT-MEL-8 INT-MEL-9 INT-MEL-10
—P 1P 22mAb 1mAb 2mAb 1mAb 2mAb 1mAb
1 s.c. met. 3 nonbrisk Empty T2 25¶ 24 28 49 50 49 37 23 28
T2 loaded with
Melan-A/Mart-127–35 8 75 76 5 6 70 5 20
2 LN met. 9 nonbrisk Empty T2 58 66 53 76 71 82 61 44 54
T2 loaded with
Melan-A/Mart-127–35 15 93 13 82 39 100 15 11 18
3 LN met. 16 absent Empty T2 54 72 59 81 83 62 57 44 64
T2 loaded with
Melan-A/Mart-127–35 41 59 44 79 84 60 51 43 63
*The subcutaneous metastasis (s.c. met.) from patient 1 was removed 8 d before CTLp frequency evaluation in peripheral blood. The lymph node
metastases (LN met.) from patients 2 and 3 were removed 6 d after and the same day of, respectively, CTLp frequency evaluation in peripheral
blood.
‡See Table VIII for characteristics of these lesions.
§T cell cultures were set up by coculture of patients’ PBLs with T2 cells either unloaded or loaded with peptide Melan-A/Mart-127–35. T cell lines
were tested on day 21 of culture.
iTargets were HLA-A*02011 9742 LCL, either unloaded (—) or loaded with Melan-A/Mart-127–35 (P1) or tyrosinase366–378 (P2) peptides, two
HLA-A*02011Melan-A/Mart-11 melanomas (INT-MEL-8 and INT-MEL-9), and one HLA-A*02011Melan-A/Mart-12 melanoma (INT-MEL-
10). Lysis of melanoma cells was tested after target preincubation (1mAb) or no preincubation (2mAb) with anti–HLA-A2 A28 mAb CR11.351.
¶Results expressed as percent lysis in a 4-h 51Cr-release assay. E/T ratio was 10:1. Values in bold represent significant lysis of peptide-loaded 9742
LCL, in comparison to empty targets or lysis of melanoma cells significantly inhibited by mAb CR11.351 (SNK test, P 5 0.01).6
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Table VIII. Immunohistochemical Analysis of Melanoma Lesions
Patient *Date ‡CTLp
Lesion
number
§Tumor
sample
iEvidence
of tumor 
regression
¶HLA class I 
on fresh tumor
¶HLA-A2 on
fresh tumor
**CD31
lymphocyte
infiltrate
‡‡CD81
lymphocyte
infiltrate
Melan-A/Mart-1 expression
§§Positive cells
iiStaining
intensity
d/m/y %%
1 04/02/91 1 PR Necr. (5%) Absent 20 111 (50%)
1 (50%)
04/02/91 2 PR¶¶ No Nonbrisk 30 0
27/03/91 3 s.c. met. No 95/371 91/225 Nonbrisk 30 90
29/03/91 4 LN met. Necr. (1%) Absent ,1 1
04/04/91 High
24/10/91 5 s.c. met. No Brisk 100 50 1 (20%)
1/2 (80%)
24/10/91 6 s.c. met. No Brisk 95 0
24/10/91 7 s.c. met. No Brisk 95 40 1 (20%)
1/2 (80%)
2 29/05/90 8 PR NA NA NA
04/07/91 High
10/07/91 9 LN met. Necr. (50%) 100/312 92/170 Nonbrisk 100 15 111 (20%)
1 (80%)
6 11/80 10 PR NA NA NA
23/01/92 High
27/01/92 11 S.T. met. Scler. (10%) 100/69 89/56 Absent 0
9 28/10/87 12 PR Scler. (10%) 0 0 Absent 70 111 (60%)
11 (40%)
28/10/87 13 s.c. met. No 0 0 Absent 50 111 (30%)
11 (70%)
28/10/87 14 LN met. No 0 0 Absent 80 111 (70%)
21/04/88 High 11 (30%)
3 23/04/91 15 PR No Absent 5 1 (100%)
14/10/91 Low
14/10/91 16 LN met. Necr. (30%) 94/80 95/32 Absent 20 111 (70%)
11 (30%)
14/10/91 17 LN met. Necr. (1%) Absent 5 111 (100%)
4 16/12/85 18 PR No 100/169 82/83 Nonbrisk 50 ,1 1
16/12/85 19 LN met. H.Necr. (1%) Nonbrisk 20 0
(continues)6
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Table VIII. (continued)
Patient *Date ‡CTLp
Lesion
number
§Tumor
sample
iEvidence of
tumor
regression
¶HLA
class I on fresh
tumor
¶HLA-A2 on
fresh tumor
**CD31
lymphocyte
infiltrate
‡‡CD81
lymphocyte
infiltrate
Melan-A/Mart-1 
expression
§§Positive
cells
iiStaining
intensity
19/01/87 20 S.T. met. H.Necr. (1%) Absent 0
19/01/87 21 S.T. met. No Absent 0
29/06/87 Low
5 09/93 22 PR*** No ND 80 Absent 0
08/11/95 23 s.c. met. Scler. (30%) 100/98 95/118 Absent 20 111 (90%)
11 (10%)
10/11/95 Low
17/10/96 24 LN met. H.Necr. (5%) Absent 60 11 (40%)
Scler. (5%) 1 (60%)
7 24/09/91 25 PR No Absent 20 111
27/01/93 26 LN met. H.Necr. (25%) Brisk 100 ,1 1
Scler. (15%)
04/03/96 Low
8 31/08/91 27 PR No Nonbrisk 100 70 11 (30%)
1 (70%)
11/12/91 28 LN met. Scler. (20%) Brisk 50 30 11 (95%)
19/02/96 Low 111 (5%)
*Date of the surgical isolation of the different neoplastic lesions from each patient or of the isolation of PBLs for CTLp frequency analysis.
‡Patients were classified according to the two subsets of Melan-A/Mart-127–35–specific CTLp frequency: patients in the 1/2,000 range are coded as high, whereas patients in the #1/40,000 range are coded as low.
§Tumor specimens were from primitive lesions (PR) rather than from subcutaneous (s.c. met.), lymph node (L.N. met.), soft tissue (S.T. met.) metastases.
iEvidence of tumor regression in each tissue section was coded as follows: absent (No), sclerosis (Scler.), necrosis (Necr.), or hemorrhagic necrosis (H.Necr.). The numbers in parentheses refer to
the percentage of the area of neoplastic tissue showing the indicated type of regression. In all instances, with no exceptions, areas of tumor regression were never associated with infiltrating leuko-
cytes but were often characterized as ischemic lesions.
¶Analysis was performed in the indicated cases on freshly isolated tumor cells from the same surgical specimen used for histological analysis. Expression of HLA class I antigens (as evaluated by stain-
ing with w6/32 mAb directed to a monomorphic determinant on all class I alleles) and HLA-A2 antigens (the restricting element for Melan-A/Mart-127–35 peptide) on tumor cells was evaluated by
flow cytometry, as all available anibodies cannot detect HLA-A2 on paraffin-embedded sections. Results expressed as percent positive cells/mean fluorescence intensity on a four-decade log scale.
**CD31 lymphocytes infiltrating the neoplastic tissue were identified by staining sections with anti-CD3 antibody and coded using the brisk/nonbrisk/absent classification (reference 2). NA, not
available.
‡‡CD81 lymphocytes infiltrating the neoplastic tissue were analyzed only in serial sections of lesions showing a brisk or nonbrisk CD31 infiltrate. Results are expressed as percentages of the brisk or
nonbrisk CD31 lymphocytes that expressed CD8.
§§Percent positive cells staining with mAb M27C10 (anti–Melan-A/Mart-1).
iiIntensity of staining for Melan-A/Mart-1 was coded as: 1/2, very weak; 1, weak; 11, moderate; and 111, strong in comparison to negative and positive controls. Percentages of cells show-
ing each of the previous three patterns are reported in parentheses.
¶¶A satellitosis from the same primitive lesion was also obtained.
***Frozen sections from this lesion were available, thus allowing staining for HLA-A2 antigens by CR11.351 mAb.662 Expanded T Cell Population to Melan-A/Mart-1
Figure 2 (continues on facing page).
escape from immune surveillance. All of these lesions ex-
pressed an absent pattern of CD31 T cells; no evidence of
tumor regression was observed in the two metastatic le-
sions, and only 10% sclerosis was documented in the pri-
mary lesion.
Furthermore, in patients 1, 2, 6, and 9, in spite of an ex-
panded pool of Melan-A/Mart-1–specific T cells in pe-
ripheral blood, further disease progression occurred due to
inoperable metastases at visceral organs or the brain. All of
these patients died within 16 (patient 1), 1 (patient 2), 5
(patient 6), and 3 mo (patient 9) after CTLp evaluation, as
summarized in Table I. In addition, in 12/14 neoplastic le-
sions from the group of patients with low CTLp frequency,
infiltrating T cells, Melan-A/Mart-1, or both were missing
(Table VIII, lesions 15–26 and Fig. 2 I–L).
Taken together, these data strongly suggest that an ex-663 Anichini et al.
Figure 2. Immunohistochemical analysis of neoplastic lesions. Three examples of immunohistochemical analysis of neoplastic lesions from three pa-
tients are reported. Consecutive sections of paraffin-embedded tumor fragments were subjected to immunohistochemical staining with anti-CD3 (A, E,
and I), anti-CD8 (B, F, and J) and anti–Melan-A/Mart-1 mAbs (C, G, and K) or conventionally stained with hematoxylin and eosin (D, H, and L). Patient
1 (Table VIII, lesion 7), A–D: a subcutaneous lesion showed no evidence of tumor regression or necrosis but did show an intense intratumoral lympho-
cytic infiltrate (D) characterized by CD31 (A) and CD81 (B) cells in the presence of heterogeneous cytoplasmatic reactivity for Melan-A/Mart-1 in tu-
mor cells (C). Patient 2 (lesion 9), E–H: a nodal metastasis with extended coagulative necrosis with strong cytoplasmic eosinophilia of cell shadows lack-
ing nuclei and scattered granulocytes infiltrating the border of the necrotic area (H, right side). The left side of the lesion, containing vital tumor cells,
showed a nonbrisk lymphocytic infiltrate (H) mostly characterized by CD31 T cells (E) but with a few CD81 lymphocytes (F). In this lesion, heteroge-
neous cytoplasmatic positivity for Melan-A/Mart-1 in neoplastic cells was confined to a small area (G). Patient 3 (lesion 16), I–L: a nodal metastasis with-
out evidence of tumor regression and lacking intratumoral lymphocytes (L), either CD31 (I) or CD81 (J), showed intense cytoplasmatic reactivity for
Melan-A/Mart-1 limited to a few neoplastic cells (K). Original magnification was 400 for all panels except for H, magnification 250).664 Expanded T Cell Population to Melan-A/Mart-1
panded pool of antigen-specific T cells in peripheral blood
cannot overcome tumor escape mechanisms in neoplastic
lesions, even when peptide-specific T cells are present in
the neoplastic tissue, as shown for patients 1 and 2.
Discussion
By coupling a high efficiency LDA assay to dissection of
memory versus naive T cell subsets, we obtained evidence
that the Melan-A/Mart-127–35 peptide is immunogenic in
vivo in a fraction of metastatic melanoma patients, as docu-
mented by the presence of an expanded peripheral pool of
antigen-specific CD45RO1 memory T cells. In the pa-
tients with an expanded T cell population to Melan-A/
Mart-127–35, the high CTLp frequency correlated with
faster kinetics of CTL development and a higher number of
effectors obtained in vitro after activation with peptide-
loaded professional APCs in comparison to patients with
low CTLp frequency. The first implication of our findings
for immune intervention strategies is that activation of
tumor-specific T cells by professional APCs will be much
more efficient, in quantitative terms (total number of effec-
tors that can be generated), in patients with an expanded
peripheral pool of memory T cells than in patients with a
low-frequency naive repertoire.
The results obtained in the patients with high CTLp fre-
quency are in agreement with data on memory phenotype
of circulating CTLp to Melan-A/Mart-1 recently reported
by D’Souza et al. (22) and with studies that have examined
the response to viral antigens like those encoded by hepati-
tis C virus, herpes simplex virus, and Epstein-Barr virus
(23–25). In such studies, viral peptide–specific precursor
frequency in infected individuals was 10–100-fold higher
than in noninfected controls, and antigen-specific precur-
sors were mostly in the CD45RO1 subset. Furthermore,
our results corroborate the findings indicating accelerated
kinetics of Melan-A/Mart–specific CTL development in
patients versus healthy donors (7).
In patients with low CTLp frequency, Melan-A/Mart-
127–35–specific precursors were found only in the
CD45RA1 naive T cell subset. No evidence of immuno-
suppression was found in these patients, as shown by analysis
of frequency of Flu matrix58–66–specific CTLp in compari-
son to healthy donors. In addition, activation and expan-
sion of Melan-A/Mart-127–35 CTLs could be obtained only
by using professional APCs. These data indicate that these
patients have a naive immune repertoire against Melan-A/
Mart-127–35, and expansion of Melan-A/Mart-127–35–spe-
cific precursors did not occur during tumor growth or was
transient and unable to generate memory T cells.
Differences in the extent and mechanism of tumor anti-
gen release (26) in tumor lesions may impact on antigen
uptake and presentation by APCs, thus leading to priming
of peptide-specific T cells only in some patients. In addition,
in some but not in all patients, tumor cells may produce
factors, such as vascular endothelial cell growth factor (27),
that inhibit APC differentiation and/or function. Further-
more, Melan-A/Mart-127–35–specific precursors could be
primed, rather than tolerized, by naturally occurring epitope
mimics of Melan-A/Mart-127–35 in some but not all patients
(28, 29). These mechanisms may hamper tumor immuno-
genicity, even in the presence of an antigenic tumor.
Several reports have recently suggested that LDA may
underestimate the frequency of antigen-specific T cells in
comparison to techniques such as the ELISPOT (enzyme-
linked immunospot assay) or staining antigen-specific T cells
with MHC–peptide tetrameric complexes (for review see
reference 30). In contrast with these concerns, in this study,
evaluation of frequency of Melan-A/Mart-1–specific T
cells in peripheral blood by LDA and tetramer staining pro-
vided similar values. In addition, we obtained a frequency
range of Flu matrix–specific CTLp as high as that found by
either ELISPOT or tetramer staining in previous studies
(31, 32). The range of z1/5,000 for Flu matrix58–66–spe-
cific CTLp detected by our LDA assay in patients is at least
10-fold higher than that found by conventional LDA by
other groups (33, 34). Those studies used an LDA tech-
nique based on 8–18 d culture time (instead of 28 d as in
our study), PBMCs or B cells as APCs (instead of T2), and
up to 4 3 103 targets in the split well assay (instead of 3 3
102 as in this study). Moreover, direct comparison of our
LDA technique with tetramer staining on the same T cell
cultures provided overlapping values in the frequency of
Melan-A/Mart-1–specific effectors, both in high- and
low-frequency cultures. This suggests that our modified
LDA has improved sensitivity in detecting both high-fre-
quency and low-frequency precursors. Furthermore, in
agreement with a previous report (35), comparison be-
tween LDA and tetramer staining provided direct evidence
that all antigen-specific T cells (on the basis of tetramer
staining) were indeed functional cytotoxic T cells able to
recognize the relevant peptide (as determined by LDA), ei-
ther when exogenously added to an LCL or when endoge-
nously expressed in melanoma cells.
In at least two patients of the high CTLp frequency sub-
set, peptide-specific T cells were found in TILs from a sub-
cutaneous and a lymph node metastasis. This indicated that
in such patients, Melan-A/Mart-127–35–specific T cells could
home to neoplastic tissue. Activation of these TILs with
peptide-loaded T2 cells in bulk culture resulted in Melan-
A/Mart-1 specificity after only 3 wk of selection, a finding
consistent with absence of any irreversible functional block
of these cells and a high precursor frequency in these le-
sions. Tetramer staining of TILs from subcutaneous lesions
showed that Melan-A/Mart-127–35–specific T cells were 1/17.6
in comparison to 1/1,404 in peripheral blood of the same
patient. This observation is in agreement with a recent re-
port describing an expanded pool of Melan-A/Mart-1–spe-
cific T cells in metastatic tissue by tetramer staining (35).
Our findings also suggest that appropriate in vitro T cell ac-
tivation can rescue antitumor function of peptide-specific
T cells that infiltrate neoplastic lesions but that apparently
do not exert antitumor activity in vivo. The observation
that T cell activation with professional APCs could activate
Melan-A/Mart-1–specific CTLs from both peripheral665 Anichini et al.
blood and tumor site suggests that antigen-specific vaccina-
tion approaches may reactivate and expand antitumor T
cells in vivo. This is in agreement with the significant anti-
tumor responses obtained by initial clinical studies of
vaccination of melanoma patients with synthetic peptides
plus adjuvants or with tumor antigen–loaded DCs (36, 37).
Furthermore, our results indicate that high frequency of
CTLp to a tumor antigen impacts on CTL generation.
Thus, a possible relationship between an expanded pool of
T cells to a tumor antigen (defined as high frequency of an-
tigen-specific T cell precursors with a memory phenotype)
before vaccination and clinical response to immune inter-
vention should be evaluated in future studies.
In spite of the presence of peptide-specific T cells in the
tumor lesions and peripheral immunity to Melan-A/Mart-
127–35, the potential for immune response at the tumor site
appeared impaired in most lesions of all patients tested. In
fact, reduced/absent evidence of tumor regression was ob-
served in the majority of the lesions available for investiga-
tion. In addition, even when areas of tumor regression
were present, these areas were never associated with or sur-
rounded by infiltrating CD31 lymphocytes. In many in-
stances, areas of regression were identified as coagulative
necrosis characterized by nuclear loss and marked cytoplas-
mic eosinophilia in the absence of inflammatory infiltrate.
This is a typical aspect of ischemic lesions suggesting vascu-
lar damage or inadequate blood supply as the initial mecha-
nism leading to regression, rather than an immune-medi-
ated mechanism. Several mechanisms may impair T cell
response at the tumor site. Lack of epitope expression (due
to lack of either Melan-A/Mart-1 or HLA-A*0201) is a
possibility supported by our findings and by a large set of
reports (for review see reference 38), but several other
mechanisms could be involved. For example, loss/defective
function of TCR signaling molecules has been described in
melanoma patients (39). Activation of the defective T cells
in the presence of IL-2 can rescue TCR signaling molecule
expression and T cell function (40). Similar mechanisms,
based on defective TCR signal transduction, might explain
why peptide-specific T cells infiltrating the tumor tissue in
immunized patients may fail to destroy tumor cells in vivo
while remaining responsive to in vitro activation.
Taken together, these results suggest that in most meta-
static lesions tumor escape mechanisms can hamper T cell–
mediated immune response, even in lesions containing
Melan-A/Mart-1 CTLp and in patients with an expanded
peripheral T cell pool to the same antigen. The implication
of these findings for immune intervention approaches is
that means to overcome tumor escape mechanisms in neo-
plastic lesions may be as relevant as the attempts to induce/
boost systemic and local T cell–mediated immunity to tu-
mor antigens.
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